The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLV.f

Pneumothorax

Patients with soft tissue sarcoma metastatic to the lung i the form of subpleural nodules/masses especially if cavitary are at greater risk of developing this complication (PMID 25302110, 30285733)

Publications

Aiba H, Kimura H, Yamada S, Okamoto H, Hayashi K, Miwa S, Kawaguchi Y, Saito S, Sakai T, Tatematsu T, Nakanishi R, Murakami H

Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis.

PloS one 2021;16;e0254866 — 2021 — e0254866

Sabath B, Muhammad HA, Balagani A, Ost DE, Vakil E, Ahmed T, Vial MR, Grosu HB

Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.

BMC cancer 2018 Oct 01;18;937 — 2018 Oct 01 — 937

Çelik B, Sürücü ZP, Y?lmaz V, Çelik HK

A Case Report of Secondary Simultaneous Bilateral Pneumothorax Due to Pazopanib Treatment.

Turkish thoracic journal 2018 Jan;19;49-51 — 2018 Jan — 49-51

Nakano K, Motoi N, Tomomatsu J, Gokita T, Ae K, Tanizawa T, Matsumoto S, Takahashi S

Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis.

BMC cancer 2016 Sep 23;16;750 — 2016 Sep 23 — 750

Leuzzi G, Alessandrini G, Ferraresi V, Ferretti G, Forcella D, Facciolo F

Bilateral spontaneous pneumothorax and massive pneumomediastinum under Pazopanib therapy.

Thoracic cancer 2015 Jan;6;110-1 — 2015 Jan — 110-1

Verschoor AJ, Gelderblom H

Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series.

Clinical sarcoma research 2014;4;14 — 2014 — 14

van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenb

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Lancet (London, England) 2012 May 19;379;1879-86 — 2012 May 19 — 1879-86